Decreased B Lymphocyte Activation [PE] - N0000182156

Pharmacologic Code	N0000182156
Pharmacologic Name	Decreased B Lymphocyte Activation
Pharmacologic Concept	Physiologic Effects - [PE]
Pharmacologic Concept Description	This concept refers to the tissue, organ, or organ system effects of drug generic ingredients, organized into an organ system classification hierarchy, beneath the "Physiological Effects [PE]" concept.

The table contains 3 products whose active ingredient are classified under the same pharmacologic class Decreased B Lymphocyte Activation [PE].

	NDC	Proprietary Name	Non-Proprietary Name	Dosage Form	Route Name	Company Name	Status
	49401-088	Benlysta	Non-Proprietary Name: Belimumab	Solution	Subcutaneous	Glaxosmithkline Llc	ACTIVE
	49401-101	Benlysta	Non-Proprietary Name: Belimumab	Injection, Powder, Lyophilized, For Solution	Intravenous	Glaxosmithkline Llc	ACTIVE
	49401-102	Benlysta	Non-Proprietary Name: Belimumab	Injection, Powder, Lyophilized, For Solution	Intravenous	Glaxosmithkline Llc	ACTIVE